- Trial phase
- Phase 3
- Time to market
- Estimated at least 5+ years away, given that both Phase 3 trials have primary completion dates around 2030-2032 and no regulatory submission has been announced.
- Why 3/10
- No hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled within the next ~12 months. Both Phase 3 trials have estimated primary completion dates around 2030-2032, and velzatinib is a single asset within GSK's large diversified pipeline, so its impact on GSK's share price is limited.
The next meaningful catalyst for velzatinib is continued enrollment and data updates from the two Phase 3 trials (StrateGIST Frontline and StrateGIST 3), but neither has a near-term readout given estimated primary completion dates around 2030-2032. Investors should watch for any interim analysis announcements or potential accelerated regulatory filing pathway discussions, though none are currently scheduled. For GSK, velzatinib is one of many pipeline assets and not a near-term binary driver for the stock.
Price Chart
Executive Summary
Velzatinib (IDRX-42/GSK6042981) is an investigational oral KIT inhibitor for gastrointestinal stromal tumors (GIST) being developed by GSK plc, which acquired the asset through its $1B+ purchase of IDRx in January 2025. At ASCO 2026, Phase 1/1b data showed a 61% response rate in first-line and 35-38% in second-line GIST patients, with broad activity across KIT mutations. Two Phase 3 trials are underway: StrateGIST Frontline (velzatinib vs imatinib in first-line) and StrateGIST 3 (velzatinib vs sunitinib in second-line), but both have estimated durations of approximately 5 years with no near-term binary catalyst. The drug has FDA Fast Track and Orphan Drug designations. For GSK, a large diversified pharma, velzatinib is a promising but distant pipeline asset with limited near-term share price impact.
How It Works
Velzatinib is a pill that blocks a protein called KIT, which acts like an 'on switch' for cancer cell growth in gastrointestinal stromal tumors (GIST). Unlike older drugs that stop working when the KIT protein mutates, velzatinib is designed to hit many different versions of the mutated KIT protein at once, potentially keeping the cancer under control for longer.
Trial Status
Two Phase 3 trials are ongoing. StrateGIST Frontline (NCT07585266) comparing velzatinib vs imatinib in first-line GIST began enrollment in July 2026 and has expanded to 93 sites. StrateGIST 3 (NCT07218926) comparing velzatinib vs sunitinib in second-line GIST after imatinib opened recruitment in December 2025 with an estimated 5-year duration. Phase 1/1b StrateGIST 1 data was presented at ASCO 2026 showing a 61% response rate in first-line (n=18) and 35-38% in second-line (n=46-49) patients.
The Two-Sided Case
Upcoming Catalysts
- Continued enrollment updates from StrateGIST Frontline and StrateGIST 3 Phase 3 trials
- Potential interim analysis announcements (none currently scheduled)
- Future medical conference data presentations (e.g., ASCO GI, ESMO)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GSK plc 6-K GSK ·Originating report